General
Preferred name
LENVATINIB
Synonyms
E7080 ()
E7080 (mesylate) ()
E7080, ER-203492-00, Lenvatinib Mesylate ()
E7080 (Lenvatinib) ()
A-13861 ()
E-7080 ()
6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]-amino]phenoxy]-7-methoxy- ()
LENVATINIB MESYLATE ()
Lenvatinib (mesylate) ()
ER-203492-00 ()
KISPLYX ()
LENVIMA ()
Lenvatinib (E7080) ()
Lenvatinib (E7080) Mesylate ()
E7080 mesylate ()
Lenvatinib-d4 ()
Lenvatinib methanesulfonate ()
Lenvatinib mesilate ()
E-7080 MESYLATE ()
P&D ID
PD003669
CAS
417716-92-8
857890-39-2
2264050-65-7
Tags
drug
natural product
available
Approved by
EMA
FDA
PMDA
First approval
2015
Drug indication
Non-small-cell lung cancer
Melanoma
Hepatocellular carcinoma
Renal cell carcinoma
Ovarian cancer
Solid tumour/cancer
Thyroid cancer
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION
Lenvatinib is indicated for the treatment of following conditions.; ; - Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.; ; - Treatment of advanced renal cell carcinoma (RCC) in combination with everolimus following one prior antiangiogenic therapy.; ; - First-line treatment of unresectable hepatocellular carcinoma (HCC).
DESCRIPTION
Lenvatinib is a potent inhibitor of VEGFR-2 (KDR) and VEGFR-3 (FLT4) .
(GtoPdb)
DESCRIPTION
inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta
(Informer Set)
DESCRIPTION
Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
(PKIDB)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
26
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Clinical kinase drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Informer Set
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
57
Properties
(calculated by RDKit )
Molecular Weight
426.11
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
4.07
TPSA
115.57
Fraction CSP3
0.19
Chiral centers
0.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
FLT1
FLT3
KDR
KIT
PDGFRA
PDGFRB
FGFR1
PDGFR??
VEGFR1/FLT1
VEGFR2/KDR
VEGFR3/FLT4
FLT4, KDR
RTK inhibitor
c-Kit
FGFR
PDGFR
RET
VEGFR
FLT4
FGFR2
FGFR3
FGFR4
c-Kit,c-RET,FGFR,PDGFR,VEGFR
Compound status
FDA
Targets
KDR,FLT4
Pathway
Angiogenesis
Tyrosine Kinase/Adaptors
Chromatin/Epigenetic
Protein Tyrosine Kinase/RTK
MOA
FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor
Indication
thyroid cancer
Source data